These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 34953553)

  • 1. Long-acting injectable for HIV approved for use in the UK.
    Kirby T
    Lancet Infect Dis; 2022 Jan; 22(1):26. PubMed ID: 34953553
    [No Abstract]   [Full Text] [Related]  

  • 2. Is Long-Acting Injectable Cabotegravir Likely to Expand PrEP Coverage Among MSM in the District of Columbia?
    Levy ME; Agopian A; Magnus M; Rawls A; Opoku J; Kharfen M; Greenberg AE; Kuo I
    J Acquir Immune Defic Syndr; 2021 Mar; 86(3):e80-e82. PubMed ID: 33148996
    [No Abstract]   [Full Text] [Related]  

  • 3. Long-acting injectable antiretrovirals for HIV treatment and prevention.
    Spreen WR; Margolis DA; Pottage JC
    Curr Opin HIV AIDS; 2013 Nov; 8(6):565-71. PubMed ID: 24100877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-acting HIV drugs advanced to overcome adherence challenge.
    Dolgin E
    Nat Med; 2014 Apr; 20(4):323-4. PubMed ID: 24710366
    [No Abstract]   [Full Text] [Related]  

  • 5. Characterization of dolutegravir drug resistance in persons diagnosed with HIV after exposure to long-acting injectable cabotegravir for preexposure prophylaxis.
    Ahluwalia AK; Inzaule S; Baggaley RC; Vitoria M; Schaefer R; Schmidt HA; Rodolph M; Giron A; Jordan MR
    AIDS; 2022 Nov; 36(13):1897-1898. PubMed ID: 36172874
    [No Abstract]   [Full Text] [Related]  

  • 6. First Extended-Release Injectable Drug Therapy for HIV.
    Aschenbrenner DS
    Am J Nurs; 2021 May; 121(5):24-25. PubMed ID: 33872258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The promise and pitfalls of long-acting injectable agents for HIV prevention.
    Landovitz RJ; Kofron R; McCauley M
    Curr Opin HIV AIDS; 2016 Jan; 11(1):122-8. PubMed ID: 26633643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selection of Rilpivirine-Resistant HIV-1 in a Seroconverter From the SSAT 040 Trial Who Received the 300-mg Dose of Long-Acting Rilpivirine (TMC278LA).
    Penrose KJ; Parikh UM; Hamanishi KA; Else L; Back D; Boffito M; Jackson A; Mellors JW
    J Infect Dis; 2016 Mar; 213(6):1013-7. PubMed ID: 26563240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [News in HIV infection, long-acting injectable treatments].
    Nawej Tshikung O; Segeral O; Cavassini M; Calmy A
    Rev Med Suisse; 2023 Feb; 19(812):243-249. PubMed ID: 36723657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Satisfaction and acceptability of cabotegravir long-acting injectable suspension for prevention of HIV: Patient perspectives from the ECLAIR trial.
    Murray MI; Markowitz M; Frank I; Grant RM; Mayer KH; Hudson KJ; Stancil BS; Ford SL; Patel P; Rinehart AR; Spreen WR; Margolis DA
    HIV Clin Trials; 2018 Aug; 19(4):129-138. PubMed ID: 30445896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Off-label Use of Long-Acting Injectable Antiretroviral Therapy: A Single Center Retrospective Review of Youth Living With HIV With Detectable HIV RNA Starting Injectable Therapy.
    Rousseau A; McGrath E; Benjamins L; Cockern S; Meade J; Houston K; Breaux M; Secord E
    J Pediatric Infect Dis Soc; 2024 May; 13(5):285-287. PubMed ID: 38591356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-acting injectable cabotegravir: implementation science needed to advance this additional HIV prevention choice.
    Schmidt HA; Rodolph M; Schaefer R; Baggaley R; Doherty M
    J Int AIDS Soc; 2022 Jul; 25(7):e25963. PubMed ID: 35903882
    [No Abstract]   [Full Text] [Related]  

  • 13. Long-acting rilpivirine as potential pre-exposure prophylaxis for HIV-1 prevention (the MWRI-01 study): an open-label, phase 1, compartmental, pharmacokinetic and pharmacodynamic assessment.
    McGowan I; Dezzutti CS; Siegel A; Engstrom J; Nikiforov A; Duffill K; Shetler C; Richardson-Harman N; Abebe K; Back D; Else L; Egan D; Khoo S; Egan JE; Stall R; Williams PE; Rehman KK; Adler A; Brand RM; Chen B; Achilles S; Cranston RD
    Lancet HIV; 2016 Dec; 3(12):e569-e578. PubMed ID: 27658864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-acting drugs and formulations for the treatment and prevention of HIV infection.
    Flexner C; Owen A; Siccardi M; Swindells S
    Int J Antimicrob Agents; 2021 Jan; 57(1):106220. PubMed ID: 33166693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-acting rilpivirine for HIV prevention.
    Jackson A; McGowan I
    Curr Opin HIV AIDS; 2015 Jul; 10(4):253-7. PubMed ID: 26049950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV drug resistance monitoring in the era of dolutegravir and injectable long-acting cabotegravir in resource-limited settings.
    Washaya T; Manasa J; Kouamou V
    AIDS; 2023 Aug; 37(10):1629-1631. PubMed ID: 37450629
    [No Abstract]   [Full Text] [Related]  

  • 17. Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials.
    Rizzardini G; Overton ET; Orkin C; Swindells S; Arasteh K; Górgolas Hernández-Mora M; Pokrovsky V; Girard PM; Oka S; Andrade-Villanueva JF; Richmond GJ; Baumgarten A; Masiá M; Latiff G; Griffith S; Harrington CM; Hudson KJ; St Clair M; Talarico CL; Patel P; Cutrell A; Van Eygen V; D'Amico R; Mrus JM; Wu S; Ford SL; Chow K; Roberts J; Wills A; Walters N; Vanveggel S; Van Solingen-Ristea R; Crauwels H; Smith KY; Spreen WR; Margolis DA
    J Acquir Immune Defic Syndr; 2020 Dec; 85(4):498-506. PubMed ID: 33136751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rilpivirine long-acting for the prevention and treatment of HIV infection.
    Ferretti F; Boffito M
    Curr Opin HIV AIDS; 2018 Jul; 13(4):300-307. PubMed ID: 29794818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Experiences with long acting injectable ART: A qualitative study among PLHIV participating in a Phase II study of cabotegravir + rilpivirine (LATTE-2) in the United States and Spain.
    Kerrigan D; Mantsios A; Gorgolas M; Montes ML; Pulido F; Brinson C; deVente J; Richmond GJ; Beckham SW; Hammond P; Margolis D; Murray M
    PLoS One; 2018; 13(1):e0190487. PubMed ID: 29304154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reply to Cossu et al., "Switching to deltoid intramuscular injections maintains therapeutic trough concentrations of rilpivirine and cabotegravir in people with HIV".
    Han K
    Antimicrob Agents Chemother; 2024 May; 68(5):e0020424. PubMed ID: 38534102
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.